26 February 2024
26 February 2024
Sanofi’s rilzabrutinib improved itch, hives, and urticaria in a Phase II trial in patients with chronic spontaneous urticaria (CSU).
The acquisition will enable PCM to enhance recruitment and retention of diverse populations in decentralised clinical trials (DCTs).
GLP1Ra’s are being investigated in Alzheimer’s, fatty liver disease and strokes – where is the limit?
The trial aims to assess the tolerability, safety, pharmacokinetics and clinical activity of ADEL-Y01.
The trial aims to evaluate the efficacy and safety of the AR1001 oral therapy for more than 52 weeks.
The trial assessed Xolair in 180 subjects aged one to 55 years who were allergic to peanuts and other foods.
Symptoms of NTM lung disease include cough, fever, weight loss, weakness, and respiratory insufficiency.
The upcoming Clinical Trial Supply Europe 2024 conference will gather pharma and biotech delegates to discuss the trends and challenges in the clinical trial supply industry.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
